Human Mesenchymal Stem Cells For Bronchopulmonary Dysplasia

• Status: Recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is an open-label, single-center, dose escalation study to evaluate of safety and efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs) in premature infants for moderate and severe Bronchopulmonary Dysplasia（BPD）.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital of Chongqing Medical University

Criteria

Inclusion Criteria:

1. The participants meet the diagnostic criteria for moderate and severe BPD established by the National Institutes of Child Health and Human Development (NICHD) workshop.

2. The participants have abnormal respiratory manifestations.

3. Written consent form signed by a legal representative or a parent.

Exclusion Criteria:

1. Although mechanical ventilation or oxygen is required in participants, there are no signs of dyspnea or BPD-related changes in lung imaging, such as central apnea or diaphragm paralysis.

2. The participants who have complex congenital heart disease.

3. The participants who have severe pulmonary hypertension(cardiac ultrasound confirmed) at the time of assessment.

4. The participants who have severe respiratory tract malformation: pierre-robin syndrome, tracheobronchomalacia, vascular ring syndrome, congenital tracheal stenosis, tracheo-esophageal fistula, pulmonary emphysema, pulmonary sequestration, congenital pulmonary dysplasia, congenital pulmonary cyst, congenital spasm, etc.

5. The participants who have severe chromosome anomalies :Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc).

6. The participants who have severe congenital infection(Herpes, Toxoplasmosis, Rubella, Syphilis, AIDS, etc).

7. The participants who have severe sepsis or shock.

8. The participants who is going to have surgery 72 hours before/after this study drug administration.

9. The participants who have surfactant administration within 24 hours before this study drug administration.

10. The participants who have severe intracranial hemorrhage ≥ grade 3 or 4.

11. The participants who have active pulmonary hemorrhage or active air leak syndrome at the time of assessment.

12. The participants who have the history of other clinical studies as a participant.

13. The participants who is considered inappropriate by the investigators.